NASDAQ:OFIX - Orthofix Medical Stock Price, Forecast & News

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Orthofix Medical Inc (NASDAQ:OFIX) announced its earnings results on Monday, October, 28th. The medical device company reported $0.41 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.51 by $0.10. The medical device company had revenue of $113.50 million for the quarter, compared to analyst estimates of $117.83 million. Orthofix Medical had a positive return on equity of 9.16% and a negative net margin of 6.81%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.44 EPS. View Orthofix Medical's Earnings History.

Orthofix Medical is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Orthofix Medical.

Orthofix Medical updated its FY19 earnings guidance on Monday, October, 28th. The company provided EPS guidance of $1.55-1.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.78. The company issued revenue guidance of $460-463, compared to the consensus revenue estimate of $473.93 million.

2 analysts have issued 1 year target prices for Orthofix Medical's stock. Their forecasts range from $48.00 to $48.00. On average, they anticipate Orthofix Medical's stock price to reach $48.00 in the next year. This suggests a possible upside of 3.6% from the stock's current price. View Analyst Price Targets for Orthofix Medical.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Orthofix Medical.

News articles about OFIX stock have trended extremely negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Orthofix Medical earned a coverage optimism score of -4.0 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Orthofix Medical.

Orthofix Medical saw a decline in short interest in the month of November. As of November 15th, there was short interest totalling 378,900 shares, a decline of 21.1% from the October 31st total of 480,100 shares. Based on an average daily trading volume, of 124,800 shares, the days-to-cover ratio is presently 3.0 days. Approximately 2.1% of the shares of the company are sold short. View Orthofix Medical's Current Options Chain.

Some companies that are related to Orthofix Medical include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), ResMed (RMD), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Clovis Oncology (CLVS), Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), Madrigal Pharmaceuticals (MDGL), Zogenix (ZGNX), Allergan (AGN), Edwards Lifesciences (EW), Zoetis (ZTS) and Biogen (BIIB).

Orthofix Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include Paradice Investment Management LLC (4.27%), State Street Corp (3.63%), Oakview Capital Management L.P. (2.09%), Dalton Greiner Hartman Maher & Co. (1.76%), Man Group plc (1.23%) and Tygh Capital Management Inc. (0.74%). Company insiders that own Orthofix Medical stock include Brad Mason, Bradley V Niemann, Davide Bianchi, Kimberley A Elting, Luke T Faulstick, Rice Doug and Ronald A Matricaria. View Institutional Ownership Trends for Orthofix Medical.

OFIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Russell Investments Group Ltd., Tygh Capital Management Inc., State Street Corp, Oakview Capital Management L.P., First Trust Advisors LP, Systematic Financial Management LP and Zebra Capital Management LLC. Company insiders that have sold Orthofix Medical company stock in the last year include Brad Mason and Davide Bianchi. View Insider Buying and Selling for Orthofix Medical.

OFIX stock was bought by a variety of institutional investors in the last quarter, including Paradice Investment Management LLC, Assenagon Asset Management S.A., SG Americas Securities LLC, Dalton Greiner Hartman Maher & Co., Rice Hall James & Associates LLC, Mackay Shields LLC, Alberta Investment Management Corp and Synovus Financial Corp. View Insider Buying and Selling for Orthofix Medical.

Shares of OFIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OFIX stock can currently be purchased for approximately $46.31.

Orthofix Medical has a market capitalization of $882.44 million and generates $453.04 million in revenue each year. The medical device company earns $13.81 million in net income (profit) each year or $1.96 on an earnings per share basis. Orthofix Medical employs 954 workers across the globe.View Additional Information About Orthofix Medical.

The official website for Orthofix Medical is http://www.orthofix.com/.

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The medical device company can be reached via phone at 214-937-2000 or via email at [email protected]